CD8A and infection: Clinical relevance of the proposed TEDbody lies in the delivery of the immunodominant CTL epitope (CMVp495–503) for presentation on the most prevalent MHC-I molecule—HLA-A*02:01 (30–50% prevalence in the human population, depending on ethnicity)—according to the following facts: i) the widespread infection of adults by CMV (60–90% of the population), and ii) the unique properties of pre-existing CMVp-CTLs such as the high functional competence (mainly TEM and TEMRA) and abundance (up to ~ 11% of CD8+ T cells) [9, 23].